(CercleFinance.com) – The biopharmaceutical company Genfit, specializing in the treatment of rare liver diseases, posts a turnover for the 2023 financial year of 28.6 million euros, compared to 20.2 million for the ‘last year.
It specifies that 13.3 million in revenue is attributable to a milestone payment invoiced to Ipsen in December 2023, following acceptance of the filing of the NDA with the FDA and the filing of the MA application with the EMA for accelerated approval of elafibranor.
As of December 31, 2023, Genfit’s cash and cash equivalents amounted to 77.8 million euros (compared to 140.2 million a year previously), an amount not including the milestone payment from from Ipsen, received in February 2024.